Pocaly Marion, Lagarde Valérie, Etienne Gabriel, Dupouy Maryse, Lapaillerie Delphine, Claverol Stéphane, Vilain Sébastien, Bonneu Marc, Turcq Béatrice, Mahon François-Xavier, Pasquet Jean-Max
U876 INSERM, Université Victor Ségalen Bordeaux 2, Hématopoïèse Leucémique et Cibles Thérapeutiques, Bordeaux, France.
Proteomics. 2008 Jun;8(12):2394-406. doi: 10.1002/pmic.200701035.
Understanding the molecular basis of resistance to imatinib, a tyrosine kinase inhibitor used as front-line therapy in chronic myeloid leukemia, remains a challenge for successful treatment. In an attempt to identify new mechanisms of resistance, we performed a comparative proteomic analysis of an imatinib-resistant cell line generated from the erythroblastic cell line K562 (K562-r) for which no known mechanism of resistance has been detected. Bidimensional gel electrophoresis was carried out to compare the protein expression pattern of imatinib-sensitive and of imatinib-resistant K562 cells. Among the 400 matched spots on five pairs of gels, only 14 spots had a significantly increased or decreased expression leading to the identification of 24 proteins identified as scaffold proteins, metabolic enzymes, DNA translation and maturation, and chaperon proteins. Among the chaperon family, only Hsp70 and Hsc70 are overexpressed in K562-r, results confirmed by Western blotting. We recently reported the participation of Hsp70 overexpression in imatinib resistance whereas a role for Hsc70 has yet to be determined. Hsc70 is not involved in imatinib resistance as the inhibition of its expression by siRNA does not restore sensitivity to imatinib. In contrast, the induced decreased expression of Hsc70 was accompanied by a greater overexpression of Hsp70. This proteomic study therefore suggests opposing roles of Hsp70 and Hsc70 in imatinib resistance.
理解对伊马替尼(一种用于慢性髓性白血病一线治疗的酪氨酸激酶抑制剂)耐药的分子基础,仍然是成功治疗的一项挑战。为了试图确定新的耐药机制,我们对源自红系细胞系K562的伊马替尼耐药细胞系(K562-r)进行了比较蛋白质组学分析,该细胞系尚未检测到已知的耐药机制。进行双向凝胶电泳以比较伊马替尼敏感和耐药的K562细胞的蛋白质表达模式。在五对凝胶上的400个匹配点中,只有14个点的表达显著增加或减少,从而鉴定出24种蛋白质,这些蛋白质被确定为支架蛋白、代谢酶、DNA翻译与成熟以及伴侣蛋白。在伴侣蛋白家族中,只有Hsp70和Hsc70在K562-r中过表达,蛋白质印迹法证实了这一结果。我们最近报道了Hsp70过表达参与伊马替尼耐药,而Hsc70的作用尚未确定。Hsc70不参与伊马替尼耐药,因为用小干扰RNA抑制其表达并不能恢复对伊马替尼的敏感性。相反,Hsc70诱导的表达降低伴随着Hsp70更大程度的过表达。因此,这项蛋白质组学研究表明Hsp70和Hsc70在伊马替尼耐药中具有相反的作用。